THE USE OF ENOXAPARIN AND RIVAROXABAN IN PATIENTS WITH CHRONIC KIDNEY DISEASE

Аннотация

Chronic kidney disease (CKD) is a progressive condition that affects the structure and function of the kidneys over time. Patients with CKD are at an increased risk for thromboembolic events due to abnormalities in coagulation and fibrinolysis. Anticoagulants such as enoxaparin (a low molecular weight heparin) and rivaroxaban (a direct oral anticoagulant) are commonly used to prevent and treat thromboembolism. However, the use of these agents in CKD patients is complicated by altered pharmacokinetics and pharmacodynamics due to impaired renal clearance. This thesis aims to compare the safety and efficacy of enoxaparin and rivaroxaban in patients with CKD, considering their renal-specific limitations, adverse effects, and therapeutic outcomes.